QDEL, US2197981051

QuidelOrtho stock closed at USD 12.91 on October 16, down 7.19 percent

Published on 10/17/2026 at 19:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 630.90 million in second-quarter 2026. QuidelOrtho stock closed at USD 12.91 on October 16, 2026, down 7.19 percent on Nasdaq.

Trading levels and next date

On Nasdaq, QuidelOrtho fell 7.19 percent on October 16, 2026.
Revenue reached USD 630.90 million in the second quarter of 2026.
QuidelOrtho stock costs USD 12.91 at Nasdaq on October 16, 2026 at 4:00 p.m. EDT, down 7.19 percent versus the prior close of USD 13.91.
The next estimated earnings date is November 5, 2026.

QDEL, US2197981051, Illustration mit AI erstellt.

QuidelOrtho stock closed at USD 12.91 on October 16, 2026, down 7.19 percent from the Nasdaq prior close of USD 13.91. The move leaves the diagnostic-testing company 30.14 percent above its 52-week low and 63.71 percent below its 52-week high.

Second-quarter revenue reached USD 630.90 million

QuidelOrtho reported USD 630.90 million in revenue for the second quarter ended June 28, 2026, up 2.80 percent from the year-earlier period, according to Morningstar. The company posted a GAAP net loss of USD 92.90 million, while adjusted diluted earnings per share came to USD 0.13. The reported loss reflects a difficult profitability picture even as revenue grew.

Price position remains wide

The October 16 session ranged from USD 12.79 to USD 14.02, with volume of 1,787,830 shares against an average of 1,643,628. The 52-week range was USD 9.92 to USD 35.58, and the stock was down 54.80 percent year to date.

The range gives investors a clear placement signal: the latest close was USD 2.99 above the yearly low and USD 22.67 below the high. QuidelOrtho's shares therefore remain much nearer the lower end of the annual range than the upper end.

Valuation and November 5 date

QuidelOrtho had a market capitalization of USD 885.3 million and a trailing price-to-earnings ratio of minus 0.84 as of October 16, 2026. The next estimated earnings date is November 5, 2026, according to Yahoo Finance.

The company operates in healthcare and develops diagnostic products for laboratories, point-of-care settings, molecular testing and transfusion medicine. Its second-quarter figures provide the latest operating reference before that scheduled reporting date.

Comparison with peers

QuidelOrtho (Nasdaq, USD): minus 7.19 percent, P/E minus 0.84, market capitalization USD 885.3 million

Danaher (NYSE, USD): minus 1.06 percent, P/E 40.68, market capitalization USD 161.0 billion

Abbott Laboratories (NYSE, USD): plus 0.19 percent, P/E 33.72, market capitalization USD 181.5 billion

What the next report will clarify

The November 5 earnings release is the next dated checkpoint for revenue, profitability and the full-year outlook. Management's 2026 guidance cited by Morningstar called for reported revenue of USD 2.52 billion to USD 2.60 billion and adjusted diluted earnings per share of USD 0.65 to USD 0.90.

QuidelOrtho closed at USD 12.91 on Nasdaq on October 16, 2026 at 4:00 p.m. EDT, down 7.19 percent versus the prior close of USD 13.91.